Movement Alert｜CSPC Pharmaceutical Group Rises 3.29% in Regular Trading, Monthly Semaglutide Injection Receives FDA Clinical Trial Approval

Market Focus06-10 11:18

On June 10, CSPC Pharmaceutical Group rose 3.29% in regular trading, trading at 7.22 HKD/share, with trading volume of 290 million HKD, outperforming the broader pharmaceuticals sector.

On the news front, the company announced on June 8 that its self-developed GLP-1 receptor agonist semaglutide long-acting injection (SYH 9017) has received FDA approval to begin clinical trials in the United States. The indication covers weight management in adults who are overweight or obese. The product is designed for once-monthly administration, offering a significant compliance advantage over the currently marketed once-weekly semaglutide injection. This marks the first time a Chinese pharmaceutical company has advanced a monthly formulation of a modified new drug into the U.S. clinical stage.

Within the Pharmaceuticals sector, most peers traded lower on the day, with SBP Group down 1.1%, Hansoh Pharma down 0.21%, Hengrui Pharma down 0.57%, Luye Pharma down 1.06%, and United Lab up 0.36%, highlighting CSPC's relative outperformance driven by the pipeline catalyst.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178458810?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 11:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178458810","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CSPC Pharmaceutical Group Rises 3.29% in Regular Trading, Monthly Semaglutide Injection Receives FDA Clinical Trial Approval","media":"Market Focus","content":"<p><p>On June 10, CSPC Pharmaceutical Group rose 3.29% in regular trading, trading at 7.22 HKD/share, with trading volume of 290 million HKD, outperforming the broader pharmaceuticals sector.</p><p>On the news front, the company announced on June 8 that its self-developed GLP-1 receptor agonist semaglutide long-acting injection (SYH 9017) has received FDA approval to begin clinical trials in the United States. The indication covers weight management in adults who are overweight or obese. The product is designed for once-monthly administration, offering a significant compliance advantage over the currently marketed once-weekly semaglutide injection. This marks the first time a Chinese pharmaceutical company has advanced a monthly formulation of a modified new drug into the U.S. clinical stage.</p><p>Within the Pharmaceuticals sector, most peers traded lower on the day, with SBP Group down 1.1%, Hansoh Pharma down 0.21%, Hengrui Pharma down 0.57%, Luye Pharma down 1.06%, and United Lab up 0.36%, highlighting CSPC's relative outperformance driven by the pipeline catalyst.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CSPC Pharmaceutical Group Rises 3.29% in Regular Trading, Monthly Semaglutide Injection Receives FDA Clinical Trial Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CSPC Pharmaceutical Group Rises 3.29% in Regular Trading, Monthly Semaglutide Injection Receives FDA Clinical Trial Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-10 11:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 10, CSPC Pharmaceutical Group rose 3.29% in regular trading, trading at 7.22 HKD/share, with trading volume of 290 million HKD, outperforming the broader pharmaceuticals sector.</p><p>On the news front, the company announced on June 8 that its self-developed GLP-1 receptor agonist semaglutide long-acting injection (SYH 9017) has received FDA approval to begin clinical trials in the United States. The indication covers weight management in adults who are overweight or obese. The product is designed for once-monthly administration, offering a significant compliance advantage over the currently marketed once-weekly semaglutide injection. This marks the first time a Chinese pharmaceutical company has advanced a monthly formulation of a modified new drug into the U.S. clinical stage.</p><p>Within the Pharmaceuticals sector, most peers traded lower on the day, with SBP Group down 1.1%, Hansoh Pharma down 0.21%, Hengrui Pharma down 0.57%, Luye Pharma down 1.06%, and United Lab up 0.36%, highlighting CSPC's relative outperformance driven by the pipeline catalyst.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1178458810","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178458810","pubTimestamp":1781061536,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 10, CSPC Pharmaceutical Group rose 3.29% in regular trading, trading at 7.22 HKD/share, with trading volume of 290 million HKD, outperforming the broader pharmaceuticals sector.On the news...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"动静快讯|石药集团常规交易涨3.29%月索马鲁肽注射液获FDA临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"On June 10, CSPC Pharmaceutical Group rose 3.29% in regular trading, trading at 7.22 HKD/share, with trading volume of 290 million HKD, outperforming the broader pharmaceuticals sector.On the news front, the company announced on June 8 that its self-developed GLP-1 receptor agonist semaglutide long-acting injection (SYH 9017) has received FDA approval to begin clinical trials in the United States. The indication covers weight management in adults who are overweight or obese. The product is designed for once-monthly administration, offering a significant compliance advantage over the currently marketed once-weekly semaglutide injection. This marks the first time a Chinese pharmaceutical company has advanced a monthly formulation of a modified new drug into the U.S. clinical stage.Within the Pharmaceuticals sector, most peers traded lower on the day, with SBP Group down 1.1%, Hansoh Pharma down 0.21%, Hengrui Pharma down 0.57%, Luye Pharma down 1.06%, and United Lab up 0.36%, highlighting CSPC's relative outperformance driven by the pipeline catalyst.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178458810","isCrawlerRequest":true}